A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

18:00 EDT 27th May 2015 | BioPortfolio

Summary

This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo.

The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Conditions

Obesity

Intervention

CJC 1295

Status

Terminated

Source

ConjuChem

Results (where available)

View Results

Links

Clinical Trials [319 Associated Clinical Trials listed on BioPortfolio]

Re-Energize With Nutrition, Exercise and Weight Loss

The purpose of this project is to establish a Center of Excellence in Research on Obesity that will focus on severe obesity. The prevalence of severe obesity (i.e., Class 2 and 3 obesity;...

Parents As The Agent Of Change For Childhood Obesity (PAAC)

The objective of this study is to test and evaluate the effectiveness of a parent-only treatment for childhood obesity. This study provides state-of-the-art treatment for childhood obesit...

Comparison of Workplace Obesity Management Programs

The purpose of this study is to design and demonstrate the feasibility of implementing moderate and intensive environmental obesity prevention programs at major worksites.

Childhood Obesity Prevention Program for Hispanics

The purpose of this study is to evaluate the efficacy of a culturally-appropriate childhood obesity intervention with Hispanic families. The program aims at preventing childhood obesity b...

Genetics of Obesity in Chinese Youngs

The purpose of this study is to explore the pathogenesis and genetic susceptibility of obese subjects,providing a convincing argument for further treatment of obesity and metabolic syndrom...

PubMed Articles [2378 Associated PubMed Articles listed on BioPortfolio]

Estimating the lifetime cost of childhood obesity in Germany: Results of a Markov Model.

Child obesity is a growing public health concern. Excess weight in childhood is known to be associated with a high risk of obesity and obesity-related comorbidities in adulthood.

Prevalence of abdominal obesity in adolescents 2012, birjand, East of iran.

Prevalence of obesity in children has been increased during recent decades all over the world. Obesity, particularly, abdominal obesity (AO) is associated with the risk of metabolic syndrome and cardi...

How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals.

A survey of obesity medicine specialists was conducted before the approval of new obesity medications in 2012.

Comorbidity associated with obesity in a large population: The APNA study.

Overweight and obesity are major causes of comorbidities which can lead to further morbidity and mortality. The main objective of the present study was to estimate the comorbidity associated with obes...

Obesity and Its Relationship with Hypertension among Adults 50 Years and Older in Jinan, China.

The relationship between obesity and hypertension varies with geographical area, race and definitions of obesity. Our study aimed to investigate the prevalence of obesity using standard Chinese criter...

Medical and Biotech [MESH] Definitions

A condition of having excess fat in the abdomen. Abdominal obesity is typically defined as waist circumferences of 40 inches or more in men and 35 inches or more in women. Abdominal obesity raises the risk of developing disorders, such as diabetes, hypertension and METABOLIC SYNDROME X.

The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.

A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

The discipline concerned with WEIGHT REDUCTION in patients with OBESITY.

More From BioPortfolio on "A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

The top 5 most promising drugs (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014 Drug Disease Company Gazyva™ Chronic lymphocytic leukemia Biogen Idec/Genentech/ F. Hoffman-La Roche ...

Endocrinology
Latest News Clinical Trials Research Drugs Reports Corporate
Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of hormones; Reproductive/Sex hormones such as FSH, LH, Oestrogen and Testosterone can affect fertility, se...

Advertisement

Searches Linking to this Trial